Memorial Sloan Kettering Cancer Center

This study compares a very low dose of radiation (4 Gy) to the standard dose (24 Gy) for people with follicular or marginal zone lymphoma. The goal is to see if the low dose works just as well to control the cancer and prevent new spots from forming, while causing fewer side effe…

This study tests whether adding surgery and precise radiation to standard treatment can cure people with HER2-positive breast cancer that has spread to 5 or fewer places in the body. About 162 adults will be randomly assigned to get either standard care alone or standard care plu…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, for people with advanced solid cancers that have not responded to standard treatments. The study aims to find the safest dose of MQ710 when given alone or with the immunothe…

This study tests a drug called ZEN003694 in people with advanced squamous cell lung cancer that has a specific change in the NSD3 gene. The drug works by blocking certain proteins that may help the cancer grow. The goal is to see if the drug can shrink or slow the cancer. About 1…

This study is testing whether a shorter course of radiation (1 week instead of the usual 5 weeks) combined with chemotherapy (carboplatin and paclitaxel) is practical for people with stage III endometrial cancer. The main goal is to see if most participants can complete all 6 pla…

This study tests whether adding a new drug (ulixertinib) to the standard treatment (ruxolitinib) is safe and effective for people with myelofibrosis, a type of bone marrow cancer. About 37 adults who are already on a stable dose of ruxolitinib will take part. The goal is to find …

This early-stage study is testing a new drug called 2141-V11 for safety in people with a type of bladder cancer that hasn't improved with standard treatment. The drug is given directly into the bladder through a thin tube (catheter). About 55 people will take part to find the saf…

This study tests whether adding a precise radiation dose to liver tumors can make standard immunotherapy work better for people with advanced non-small cell lung cancer that has spread to the liver. About 68 adults with stage IV NSCLC will either get standard drug therapy alone o…

This early-phase study tests the safety of combining two drugs, ruxolitinib and duvelisib, in people with T- or NK-cell lymphoma that has come back or not responded to prior treatments. About 70 participants will receive the drugs to find the best dose and see if the combination …

This study tests whether combining ivonescimab with either Dato-DXd or osimertinib is safe and works for people with advanced EGFR-mutant non-small cell lung cancer that stopped responding to previous treatments. About 66 adults will join. Researchers will first find the best dos…

This study tests whether the drug sotorasib is safe and effective as the first treatment for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 39 adults who have not yet received any treatment for their advanced cancer will…

This study tests a drug called pasireotide in 10 adults with prolactinomas (pituitary tumors) who cannot use standard dopamine agonist therapy due to side effects, contraindications, or resistance. The goal is to see if pasireotide can safely lower prolactin levels to normal and …

This study looks at people with a specific type of advanced lung cancer (EGFR-mutant) that has spread. It compares the usual treatment, a pill called osimertinib, against osimertinib plus chemotherapy. The goal is to see if the combination can keep the cancer from growing longer.…

This study tests whether a combination of two non-chemotherapy drugs (vemurafenib and obinutuzumab) causes fewer side effects than the standard chemotherapy-based treatment (cladribine plus rituximab) for people with untreated hairy cell leukemia. About 86 adults with a specific …

This study tests whether adding the drug pembrolizumab to standard chemotherapy (GVD) can help people with Hodgkin lymphoma that has returned or not responded to initial treatment. About 257 participants will receive the combination, and those who respond well may go on to a stem…

This study tests the drug cabozantinib in people with advanced non-small cell lung cancer that has certain gene changes (RET, ROS1, NTRK fusions, or increased MET or AXL activity). The goal is to see if the drug can shrink tumors and stop them from growing. About 86 participants …

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic breast cancer. The goal is to see if these combinations can shrink tumors better than r…

This study is testing whether a lower dose of the drug brentuximab vedotin can still effectively treat mycosis fungoides, Sezary syndrome, and lymphomatoid papulosis—types of skin lymphoma. About 58 adults with stage IB or higher disease will receive the lower dose to see if it w…

This early-stage study tests whether combining two drugs, valemetostat and atezolizumab, is safe for people with extensive-stage small cell lung cancer. About 24 adults will receive different doses of valemetostat alongside atezolizumab to find the best dose with the fewest side …

This study tests a radioactive drug called I-MIBG in people with neuroblastoma or related tumors that have not responded to standard treatments. The drug delivers radiation directly to cancer cells to shrink tumors. Researchers want to see how well it works and how safe it is for…

This study is for people with a type of lung cancer (NSCLC) that has spread to the brain. It compares two approaches: taking a targeted cancer pill (osimertinib) alone versus adding a precise form of radiation (SRS) after three months of the pill. The goal is to see which strateg…

This study tests whether giving two drugs—enfortumab vedotin and pembrolizumab—before bladder cancer surgery can eliminate cancer in the lymph nodes and shrink tumors. About 23 adults with advanced bladder cancer that has spread to lymph nodes will receive the combination before …

This study tests whether adding the drug certolizumab to standard chemotherapy and immunotherapy helps shrink stage II-III lung cancers before surgery. The goal is to see if this combination leads to fewer cancer cells remaining after treatment. About 60 adults with operable lung…

This early-stage study tests whether combining two drugs, teclistamab and mezigdomide, is safe and works for people with multiple myeloma that has come back or stopped responding to other treatments. About 18 adults who have already tried at least two prior therapies will take pa…

This study tests whether two drugs, avutometinib and defactinib, can shrink or control advanced or recurrent mesonephric gynecologic cancer, a rare type of cancer. About 40 women with this cancer will receive the drug combination. The goal is to see how well the treatment works a…

This study tests whether two drugs, avutometinib and defactinib, can shrink or control thyroid cancers that have a specific genetic change (RAF dimer-driven) and no longer respond to radioactive iodine. About 30 adults with either differentiated or anaplastic thyroid cancer will …

This study tests whether a single, high-dose session of MRI-guided radiation can stop colorectal cancer liver metastases from growing. About 32 adults with up to 3 small liver tumors will receive the treatment and be monitored for tumor control and side effects. The goal is to co…

This study tests if Vonescimab can safely shrink or slow advanced leiomyosarcoma, a rare soft-tissue cancer. About 20 adults who have already had 1-3 prior treatments will receive the drug. The main goal is to see how many patients respond to treatment.

This study looks at whether people with plasma cell disorders can safely recover from a stem cell transplant at home instead of in the hospital. About 91 adults will receive their transplant and then be cared for at home or a home-like setting. The goal is to see if this approach…

This study is for people with metastatic breast cancer whose disease has started to grow in just one spot. Researchers want to see if giving a precise, high-dose radiation treatment (SBRT) to that spot, while continuing usual drug therapy, can stop the cancer from spreading furth…

This early-phase trial tests a new drug, CRD3874-SI, which activates the immune system to fight cancer. It is for people with advanced solid tumors like sarcoma or Merkel cell carcinoma that have not responded to other treatments. The main goals are to find the safest dose and se…

This early-phase study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people with central nervous system (CNS) lymphoma that has returned or not improved with prior therapy. About 26 adults will take part. The main goal is to see what side effects occur…

This study tests a procedure called gastric preconditioning, done before esophageal cancer surgery, to see if it lowers the risk of a serious complication called an anastomotic leak. The study enrolls 40 people at high risk for this leak. The procedure uses a tiny tube to block c…

This early-phase study tests whether adding abemaciclib to the standard drug ruxolitinib is safe and effective for people with myelofibrosis, a type of bone marrow cancer. About 18 adults who have been on ruxolitinib for at least 12 weeks will receive the combination. The main go…

This study tests a new treatment plan for people aged 65 and older with diffuse large B-cell lymphoma (DLBCL) or related lymphomas. The treatment combines the standard chemotherapy (R-miniCHP) with three newer drugs (glofitamab, polatuzumab, and obinutuzumab) to see if it can imp…

This study looks at whether a blood test that detects tumor DNA (ctDNA) can guide decisions to stop maintenance immune therapy after one year in people with advanced or recurrent endometrial cancer. About 30 participants will receive standard chemotherapy plus immune therapy for …

This study tests a bivalent vaccine (with an immune booster called OPT-821) plus oral β-glucan in 94 people with high-risk neuroblastoma that is in complete remission. The goal is to see which schedule of β-glucan helps the body make more antibodies against the cancer, potentiall…

This study tests a new treatment plan for people newly diagnosed with a blood cancer called multiple myeloma. Participants will receive two different drug combinations in alternating cycles to see if this approach is safe and can make the cancer undetectable. The trial is for 65 …

This study trains Nigerian radiologists to perform ultrasound-guided breast biopsies using mobile health devices. The goal is to create a sustainable way to improve breast cancer diagnosis in areas with limited resources. About 900 women with suspicious breast lumps will take par…

This study is testing whether a new imaging method called 68Gallium PSMA-PET/CT can find cancer spots in people with metastatic bladder cancer or melanoma. About 20 participants will get both the new scan and a standard FDG-PET/CT scan to compare results. The goal is to see if th…

This study tests whether a buried fat flap procedure is safe and helpful for reducing neck problems like pain, stiffness, and trouble swallowing after head and neck cancer treatment. About 12 adults who have had radiation and a neck dissection will receive the flap. Researchers w…

This study looks at whether a single 60-minute counseling session can help reduce anxiety and depression in people with breast cancer who are waiting for ongoing therapy. About 20 participants will try the session and report how helpful it was. The goal is to see if this short-te…

This study adapts a counseling program called Meaning Centered Psychotherapy to better support Latinos with advanced cancer. Researchers want to see if this culturally tailored approach can improve quality of life and reduce anxiety and depression. About 285 adults who identify a…

This study tests whether a single, focused dose of radiation (stereotactic radiosurgery) can safely relieve chronic pain in the chest or belly wall. About 18 adults whose pain hasn't improved with standard treatments will receive different radiation doses to find the safest and m…

This study compares two types of group therapy to help breast cancer survivors cope with joint pain caused by aromatase inhibitors (a common hormone therapy). About 200 women with a history of early-stage breast cancer who have joint pain will attend weekly 2-hour group sessions …

This study looks at whether adding gabapentin to standard pain management can reduce the need for stronger opioids after mastectomy. About 1,896 adults aged 18 to 65 having same-day mastectomy at a single center will take part. The goal is to see if gabapentin helps control pain …

This study tests a new type of radiation therapy called lattice radiation therapy (LRT) for people with advanced solid tumors that have spread to soft tissues. The goal is to see if LRT works better than standard radiation at shrinking tumors and helping the immune system fight c…

This study collects blood, tissue, and stool samples from 160 people aged 18-49, including those with young onset colorectal cancer and healthy volunteers. Researchers will analyze the samples to learn more about what causes this cancer in younger adults. No treatment is given; t…

This study uses advanced MRI scans to better predict which parts of a malignant glioma (brain tumor) are most likely to grow back after treatment. Researchers hope this will help design safer and more effective radiation plans. The study includes 135 adults with suspected or conf…

This study looks at whether a new type of MRI scan, which uses a special imaging agent called hyperpolarized pyruvate, gives the same results each time it is used in the same person. About 109 people with solid tumors will have two of these scans to check for consistency. The goa…

This study creates a database of health information from 250 people diagnosed with desmoplastic small round cell tumor (DSRCT), a rare cancer. Participants of any age can join by sharing their medical history and ongoing health data. Researchers will use this information to learn…

This study looks at how a marker called Ki67 changes in breast cancer cells after hormone therapy in people with and without a BRCA2 gene mutation. About 42 postmenopausal women with ER+/HER2- breast cancer will take hormone therapy before surgery. Researchers want to see if the …

This study is for women with a suspicious breast finding or newly diagnosed breast cancer. Researchers will collect tissue, blood, and questionnaire data to learn how genetics and other factors affect breast cancer risks and outcomes. The study does not provide any treatment, but…

This study looks at how men aged 45-70 with BRCA1/2 gene mutations respond to additional genetic risk testing for prostate cancer. Researchers want to understand if this extra information changes their screening choices and how it affects their emotions. The study does not offer …

This study aims to create a registry of people with early changes in the stomach lining that can lead to stomach cancer, such as gastric atrophy, intestinal metaplasia, and dysplasia. Researchers will also include healthy individuals and those with stomach cancer for comparison. …

This study aims to understand why breast cancer risk and outcomes differ among people. Researchers will collect surveys, blood, and tissue samples from 800 adults in South Florida. The goal is to identify genetic and non-genetic factors that may explain these differences.

This study is building a registry of DNA and health information from 750 people with kidney cancer, their family members, and healthy volunteers. The goal is to learn more about how to prevent, find, and treat kidney cancer in the future. Participants provide a blood or saliva sa…

This study gathers medical information from up to 100 people worldwide who have large dark skin patches present at birth or a related brain condition called neurocutaneous melanocytosis. Researchers will review past and future medical records to learn more about the disease, its …